var data={"title":"Goserelin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Goserelin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6280?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=goserelin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Goserelin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177201\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zoladex</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177202\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Zoladex;</li>\n      <li>Zoladex LA</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177239\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Gonadotropin-Releasing Hormone Agonist;</li>\n      <li>\n        Gonadotropin Releasing Hormone Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177204\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer, advanced:</b> Males: SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">28-day implant: 3.6 mg every 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">12-week implant: 10.8 mg every 12 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer, stage B2 to C (in combination with an antiandrogen and radiotherapy; begin 8 weeks prior to radiotherapy):</b> Males: SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Combination 28-day/12-week implant: 3.6 mg implant, followed in 28 days by 10.8 mg implant</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">28-day implant (alternate dosing): 3.6 mg; repeated every 28 days for a total of 4 doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, advanced:</b> Females: SubQ: 3.6 mg every 28 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometriosis:</b> Females: SubQ: 3.6 mg every 28 days for 6 months</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometrial thinning:</b> Females: SubQ: 3.6 mg every 28 days for 1 or 2 doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of early menopause during chemotherapy for early stage hormone receptor negative breast cancer (off-label use):</b> Adult females: SubQ: 3.6 mg every 28 days starting 1 week prior to the first chemotherapy dose; continue until within 2 weeks before or after the final chemotherapy dose (Moore 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990346\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987714\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">No dosage adjustment necessary.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177205\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Males: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177180\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Implant, Subcutaneous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zoladex: 3.6 mg (1 ea); 10.8 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177166\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177183\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">SubQ: Administer implant by inserting needle at a 30- to 45-degree angle into the anterior abdominal wall below the navel line. Use caution while injecting goserelin into the anterior abdominal wall (due to the proximity of underlying inferior epigastric artery and its branches). Goserelin is an implant; therefore, do not attempt to eliminate air bubbles prior to injection (may displace implant). Do not attempt to aspirate prior to injection; if a large vessel is penetrated, blood will be visualized in the syringe chamber (if vessel is penetrated, withdraw needle and inject elsewhere with a new syringe). Do not penetrate into muscle or peritoneum. Implant may be detected by ultrasound if removal is required. Monitor for signs/symptoms of abdominal hemorrhage. Use extra care when administering goserelin to patients with a low BMI and/or to patients receiving full dose anticoagulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132607\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and (when dosage form allows) closed system transfer devices (CSTDs) for compounding. Double gloves and a protective gown are required during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177181\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer, advanced (3.6 mg only):</b> Palliative treatment of advanced breast cancer in pre- and perimenopausal women (estrogen and progesterone receptor values may help to predict if goserelin is likely to be beneficial).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometrial thinning (3.6 mg only):</b> Endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Endometriosis (3.6 mg only):</b> Management of endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy (goserelin experience for endometriosis has been limited to women 18 years and older treated for 6 months).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer, advanced (3.6 mg or 10.8 mg):</b> Palliative treatment of advanced carcinoma of the prostate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prostate cancer, stage B2 to C (3.6 mg or 10.8 mg):</b> Management of locally confined stage T2b to T4 (stage B2 to C) prostate cancer (in combination with an antiandrogen [eg, flutamide]); begin goserelin and antiandrogen therapy 8 weeks prior to initiating radiation therapy and continue during radiation therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26629444\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Breast cancer, advanced (second-line endocrine-based combination therapy); Prevention of early menopause during chemotherapy for early stage hormone receptor negative breast cancer</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177173\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Some frequencies not defined. Percentages reported with the 1-month implant:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Vasodilatation (females 57%), peripheral edema (females 21%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (females 32% to 75%; males 1% to 5%), emotional lability (females 60%), depression (females 54%; males 1% to 5%), pain (8% to 17%), dyspareunia (females 14%), insomnia (5% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Diaphoresis (females 16% to 45%; males 6%), acne vulgaris (females 42%; usually within 1 month after starting treatment), seborrhea (females 26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Hot flash (females 57% to 96%; males 64%), decreased libido (females 48% to 61%), increased libido (females 12%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Abdominal pain (females 7% to 11%), nausea (5% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Vaginitis (75%), breast atrophy (females 33%), sexual disorder (males 21%), breast hypertrophy (females 18%), decrease in erectile frequency (18%), pelvic symptoms (females 18%), genitourinary signs and symptoms (lower; males 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Tumor flare (females 23%; males: Incidence not reported)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Infection (females 13%; males: Incidence not reported)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Decreased bone mineral density (females 23%; ~4% decrease from baseline in 6 months; male: Incidence not reported), weakness (females 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Edema (females 5%; male 7%), hypertension (1% to 6%), cardiac failure (males 5%), cardiac arrhythmia (males &gt;1% to &lt;5%), cerebrovascular accident (males &gt;1% to &lt;5%), peripheral vascular disease (males &gt;1% to &lt;5%), varicose veins (males &gt;1% to &lt;5%), chest pain (1% to &lt;5%), myocardial infarction (males &lt;1% to &lt;5%), palpitations, tachycardia (females) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Lethargy (females &le;8%), migraine (females 1% to 7%), dizziness (females 6%; male 5%), malaise (females &le;5%), chills (males &gt;1% to &lt;5%), anxiety (1% to &lt;5%), nervousness (females 3% to 5%), voice disorder (females 3%), abnormality in thinking, drowsiness, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (males 6% to 8%; female frequency not reported), hair disease (females 4%), pruritus (females 2%), alopecia, skin discoloration, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Endocrine &amp; metabolic: Gynecomastia (males 8%), hirsutism (7%), gout (males &gt;1% to &lt;5%), hyperglycemia (males &gt;1% to &lt;5%), weight gain (&gt;1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Anorexia (1% to 5%), gastric ulcer (males &gt;1% to &lt;5%), constipation (1% to &lt;5%), diarrhea (1% to &lt;5%), vomiting (1% to &lt;5%), increased appetite (females 2%), dyspepsia, flatulence, xerostomia </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Genitourinary: Pelvic pain (females 9%; males 6%), mastalgia (&gt;1% to 7%), uterine hemorrhage (6%), vulvovaginitis (5%), breast swelling (males &gt;1% to &lt;5%), urinary tract obstruction (males: &gt;1% to &lt;5%), urinary tract infection (1% to &lt;5%), urinary frequency, vaginal hemorrhage</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hematologic &amp; oncologic: Anemia (males &gt;1% to &lt;5%), bruise, hemorrhage </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hypersensitivity: Hypersensitivity reaction </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Sepsis (males &gt;1% to &lt;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Application site reaction (females 6%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Myalgia (females 3%, males frequency not reported), leg cramps (females 2%, males frequency not reported), hypertonia (females 1%; male frequency not reported), arthralgia, arthropathy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ophthalmic: Amblyopia, dry eye syndrome </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Renal: Renal insufficiency (&lt;1% to &gt;5%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Upper respiratory tract infection (males 7%), chronic obstructive pulmonary disease (males 5%), flu-like symptoms (females 5%, male frequency not reported), pharyngitis (females 5%), sinusitis (females &ge;1%; male frequency not reported), bronchitis, cough, epistaxis, rhinitis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports (with monthly or 3-month implant): Anaphylaxis, bone fracture, convulsions, decreased glucose tolerance, decreased HDL cholesterol, deep vein thrombosis, diabetes mellitus, hypercalcemia, hypercholesterolemia, hyperlipidemia, hypotension, increased HDL cholesterol, increased LDL cholesterol, increased serum ALT, increased serum AST, increased serum triglycerides, injection site reaction (including vascular injury, pain, hematoma, hemorrhage, hemorrhagic shock), osteoporosis, ovarian cyst, ovarian hyperstimulation syndrome, pituitary apoplexy, pituitary neoplasm (including adenoma), pulmonary embolism, psychotic reaction, transient ischemic attacks </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177186\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to goserelin, GnRH, GnRH agonist analogues, or any component of the formulation; pregnancy (except if using for palliative treatment of advanced breast cancer)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling: </i>Additional contraindications (not in the US labeling): Undiagnosed vaginal bleeding, pregnancy, breastfeeding</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177170\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cervical resistance: Cervical resistance may be increased; use caution when dilating the cervix for endometrial ablation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Decreased bone density: Has been reported in women and may be irreversible; use caution if other risk factors are present; evaluate and institute preventive treatment if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypercalcemia: Hypercalcemia has been reported in prostate and breast cancer patients with bone metastases. Initiate appropriate management if hypercalcemia occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperglycemia: Hyperglycemia has been reported in males and may manifest as diabetes or worsening of preexisting diabetes (worsening glycemic control). Monitor blood glucose and HbA<sub>1c</sub> and manage diabetes appropriately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (including acute anaphylactic reactions) and antibody formation may occur; monitor.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Injection site injury: Injection site and vascular injury, including pain, hematoma, hemorrhage and hemorrhagic shock (requiring blood transfusions or surgical intervention) have been reported with goserelin. Use extra caution when administering to patients with a low BMI and/or to patients receiving full dose anticoagulation. Use caution while injecting goserelin into the anterior abdominal wall (due to the proximity of underlying inferior epigastric artery and its branches). Monitor for signs/symptoms of abdominal hemorrhage. Inform patient to immediately report abdominal pain, abdominal distention, dyspnea, dizziness, hypotension, and/or altered level of consciousness.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pituitary apoplexy: Rare cases of pituitary apoplexy (frequently secondary to pituitary adenoma) have been observed with GnRH agonist administration (onset from 1 hour to usually &lt;2 weeks); may present as sudden headache, vomiting, visual or mental status changes, and infrequently cardiovascular collapse; immediate medical attention required.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor flare: Transient increases in serum testosterone (in men with prostate cancer) and estrogen (in women with breast cancer) may result in a worsening of disease signs and symptoms (tumor flare) during the first few weeks of treatment. Some patients experienced a temporary worsening of bone pain, which may be managed symptomatically. Spinal cord compression and urinary tract obstruction have been reported when used for prostate cancer; closely observe patients for symptoms (eg, ureteral obstruction, weakness, paresthesias) in first few weeks of therapy. Manage with standard treatment; consider orchiectomy for extreme cases.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Androgen deprivation therapy may increase the risk for cardiovascular disease (Levine, 2010). An increased risk for MI, sudden cardiac death, and stroke has been observed. Monitor for signs/symptoms of cardiovascular disease; manage according to current clinical practice. Androgen deprivation therapy may cause prolongation of the QT/QTc interval; evaluate risk versus benefit in patients with congenital long QT syndrome, heart failure, frequent electrolyte abnormalities, and in patients taking medication known to prolong the QT interval. Correct electrolytes prior to initiation and consider periodic electrolyte and ECG monitoring.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Obese patients: A decreased AUC may be observed when using the 3-month implant in obese patients. Monitor testosterone levels if desired clinical response is not observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Underweight patients: Use extra care when administering to patients with a low BMI.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Women: Women of childbearing potential should not receive therapy until pregnancy has been excluded. Nonhormonal contraception is recommended during therapy and for 12 weeks after therapy is discontinued. Chronic administration may result in effects on reproductive function due to antigonadotropic properties.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Implant removal: If removal is necessary, implant may be located by ultrasound.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299420\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6220698\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8500&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Choline C 11: Luteinizing Hormone-Releasing Hormone Analogs may diminish the therapeutic effect of Choline C 11. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corifollitropin Alfa: Luteinizing Hormone-Releasing Hormone Analogs may enhance the therapeutic effect of Corifollitropin Alfa. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Indium 111 Capromab Pendetide: Luteinizing Hormone-Releasing Hormone Analogs may diminish the diagnostic effect of Indium 111 Capromab Pendetide. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177177\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">X (endometriosis, endometrial thinning); D (advanced breast cancer) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177189\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction  studies. Goserelin induces hormonal changes which increase the risk for fetal loss and use is contraindicated in pregnancy unless being used for palliative treatment of advanced breast cancer. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Breast cancer: If used for the palliative treatment of breast cancer during pregnancy, the potential for increased fetal loss should be discussed with the patient.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endometriosis, endometrial thinning: Use is contraindicated during pregnancy. Women of childbearing potential should not receive therapy until pregnancy has been excluded. Nonhormonal contraception is recommended for premenopausal women during therapy and for 12 weeks after therapy is discontinued. Although ovulation is usually inhibited and menstruation may stop, pregnancy prevention is not ensured during goserelin therapy. Changes in reproductive function may occur following chronic administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9404689\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if goserelin is present in breast milk, although goserelin is inactivated when used orally. Due to the potential for serious adverse reactions in the breastfed infant, a decision should be made to discontinue breast-feeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9404926\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Monitor blood glucose and HbA<sub>1c</sub> (periodically), bone mineral density, serum calcium, cholesterol/lipids; monitor for signs/symptoms of abdominal hemorrhage following injection.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostate cancer: Consider periodic ECG and electrolyte monitoring. Monitor for weakness, paresthesias, tumor flare, urinary tract obstruction, and spinal cord compression in first few weeks of therapy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177169\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Goserelin (a gonadotropin-releasing hormone [GnRH] analog) causes  an initial increase in luteinizing hormone (LH) and follicle stimulating hormone (FSH), chronic administration of goserelin results in a sustained suppression of pituitary gonadotropins. Serum testosterone falls to levels comparable to surgical castration. The exact mechanism of this effect is unknown, but may be related to changes in the control of LH or down-regulation of LH receptors.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177185\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Females: Estradiol suppression reaches postmenopausal levels within 3 weeks and FSH and LH are suppressed to follicular phase levels within 4 weeks of initiation</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Males: Testosterone suppression reaches castrate levels within 2 to 4 weeks after initiation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Females: Estradiol, LH and FSH generally return to baseline levels within 12 weeks following the last monthly implant.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Males: Testosterone levels maintained at castrate levels throughout the duration of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: SubQ: Rapid and can be detected in serum in 30 to 60 minutes; 3.6 mg: released slowly in first 8 days, then rapid and continuous release for 28 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Male: 44.1 L; Female: 20.3 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~27%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic hydrolysis of the C-terminal amino acids</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak, serum: SubQ: Male: 12 to 15 days, Female: 8 to 22 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&gt;90%; 20% as unchanged drug) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51196153\" class=\"block phksp drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gender: The total body Cl of goserelin was significantly (<i>P</i> &lt;0.05) greater (163.9 vs 110.5 L/min) in women compared with men.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Body weight: A decline in AUC of approximately 1% to 2.5% was observed with a kg increase in body weight.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177188\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Implant</b> (Zoladex Subcutaneous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3.6 mg (1): $726.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10.8 mg (1): $2,178.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F177190\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Zoladex (AE, AR, AT, BB, BD, BE, BF, BG, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CR, CU, CY, CZ, DE, DK, DO, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, ID, IE, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KR, KW, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MY, NE, NG, NI, NL, NO, OM, PA, PE, PH, PK, PL, PR, PT, RO, RU, SC, SD, SE, SG, SK, SL, SN, SR, SV, SY, TH, TN, TR, TT, TW, TZ, UA, UG, UY, VE, VN, YE, ZA, ZM, ZW);</li>\n      <li>Zoladex Depot (AE, BH, KR, LB, QA, SA);</li>\n      <li>Zoladex Implant (AT, AU, BE, BG, CH, CZ, DE, DK, EE, FI, FR, GB, GR, HN, IE, IT, NO, PL, PT, RU, SE, SK, TR);</li>\n      <li>Zoladex Inj. (NZ);</li>\n      <li>Zoladex LA (AR, BB, BH, BM, BS, CO, CU, EC, HR, ID, IL, IN, JM, LB, LK, LU, LV, MT, MY, NL, PH, PR, QA, RO, SG, TH, TT, TW, UY);</li>\n      <li>Zpladex (SI)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. <i>J Clin Oncol</i>. 2014;32(30):3436-3448.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/25199761/pubmed\" target=\"_blank\" id=\"25199761\">25199761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baum M, Hackshaw A, Houghton J, et al. Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study. <i>Eur J Cancer</i>. 2006; 42(7):895-904.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/16545560/pubmed\" target=\"_blank\" id=\"16545560\">16545560</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Somerfield MR, Anderson H, et al. American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer [published correction appears in <i>J Clin Oncol</i>. 2012 Apr 20;30(12):1398]. <i>J Clin Oncol</i>. 2011;29(29):3939-3942.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/21900112/pubmed\" target=\"_blank\" id=\"21900112\">21900112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hackshaw A, Baum M, Fornander T, et al. Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. <i>J Natl Cancer Inst</i>. 2009; 101(5):341-349.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/19244174/pubmed\" target=\"_blank\" id=\"19244174\">19244174</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Horwitz EM, Bae K, Hanks GE, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. <i>J Clin Oncol</i>. 2008; 26(15):2497-2504.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/18413638/pubmed\" target=\"_blank\" id=\"18413638\">18413638</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levine GN, D&rsquo;Amico AV, Berger P, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk. A science advisory from the American Heart Association, American Cancer Society, and American Urological Association. <i>Circulation</i>, 2010, 121(6):833-840.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/20124128/pubmed\" target=\"_blank\" id=\"20124128\">20124128</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loren AW, Mangu PB, Beck LN, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500-2510. Available at http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2013.49.2678 Accessed September 29, 2014.23715580</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25738668\"></a>Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. <i>N Engl J Med</i>. 2015;372(10):923-932.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/25738668/pubmed\" target=\"_blank\" id=\"25738668\">25738668</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roach M 3rd, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. <i>J Clin Oncol</i>. 2008; 26(4):585-591.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/18172188/pubmed\" target=\"_blank\" id=\"18172188\">18172188</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sarosdy MF, Schellhammer PF, Soloway MS, et al. Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancer. <i>BJU Int</i>. 1999;83(7):801-806.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/10368200/pubmed\" target=\"_blank\" id=\"10368200\">10368200</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"26030518\"></a>Turner NC, Ro J, Andr&eacute; F, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. <i>N Engl J Med</i>. 2015;373(3):209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/goserelin-drug-information/abstract-text/ 26030518/pubmed\" target=\"_blank\" id=\" 26030518\"> 26030518</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zoladex 3.6 mg (goserelin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zoladex 10.8 mg (goserelin) [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; July 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zoladex (goserelin) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zoladex LA (goserelin) [product monograph]. Mississauga, Ontario, Canada: AstraZeneca Canada Inc; December 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8500 Version 125.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F177201\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F177202\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F177239\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F177204\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990346\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987714\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F177205\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F177180\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F177166\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F177183\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132607\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F177181\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F26629444\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F177173\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F177186\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F177170\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299420\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6220698\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F177177\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F177189\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F9404689\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F9404926\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F177169\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F177185\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Considerations\" href=\"#F51196153\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F177188\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F177190\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8500|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=goserelin-patient-drug-information\" class=\"drug drug_patient\">Goserelin: Patient drug information</a></li></ul></div></div>","javascript":null}